目的：探讨依达拉奉与醒脑静在急性脑出血治疗中的临床有效性。方法随机抽取2015年2月～2016年2月期间收治的急性脑出血患者62例，采用醒脑静治疗的31例为对照组，采用依达拉奉与醒脑静联合治疗的另31例为研究组，对比分析两组治疗的效果。结果研究组 NIHSS 评分、ADL 评分优于对照组（P ＜0.05）；且研究组的总有效率高于对照组（P ＜0.05）。结论依达拉奉与醒脑静联合治疗急性脑出血的临床效果确切，可有效改善患者神经功能缺损程度。%Objective To analyze clinical efficacy of Edaravone and Xingnaojing in treatment of acute cerebral hemorrhage. Methods 62 patients with acute cerebral hemorrhage were randomly selected in February 2015 - February 2016, used Xingnaojing Injection in the treatment of 31 cases as control group, and by edaravone combined with Xingnaojing Injection in the treatment of another 31 cases as study group. The effect of treatment in the two groups was compared. Results The NIHSS score, ADL score of study group were better than that of control group (P<0.05);And total effective rate of study group was higher than the control group (P<0.05). Conclusion The clinical effect of edaravone combined with Xingnaojing Injection in the treatment of acute cerebral hemorrhage exact can improve neurological function defect degree.
展开▼
